Navigation Links
Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers
Date:9/20/2013

NEW YORK, September 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), UnitedHealth Group Inc. (NYSE: UNH), Merck & Co., Inc. (NYSE: MRK), Gilead Sciences, Inc. (NASDAQ: GILD), and Bristol-Myers Squibb Co. (NYSE: BMY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 11, 2013, Fitch Ratings Inc. (Fitch Ratings) affirmed Pfizer Inc.'s (Pfizer) Issuer Default Rating (IDR) at 'A+', and provided a Stable Rating Outlook. The rating actions apply to Pfizer's approximately $36.7 billion of consolidated debt outstanding as of June 30, 2013. Some of the key rating drivers mentioned by Fitch were as follows: Fitch believes Pfizer's narrowing focus on human branded pharmaceuticals will improve long-term profitability and growth, offsetting the negative effect of a less-diversified business model; the Company's patent cliff is becoming less steep as a smaller percentage (approximately 20%) of branded revenues are exposed to patent expiration in the next three years; one of Pfizer's at-risk branded products (Enbrel) which Fitch expects will lose less market share to biosimilar competition than the 80% to 90% that typically occurs with generic competition to small molecule drug; Pfizer is making decent progress in developing and commercializing a pipeline of the new drugs; and despite the Company's recent drug launches, Fitch expects Pfizer will generate relatively flat organic revenues through 2016. Als
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
4. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
5. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
6. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
7. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
8. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
9. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
10. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
11. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Depomed, Inc. (Nasdaq: ... offer, subject to market and other conditions, $230 million ... (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the ... up to an additional $34.5 million aggregate principal amount ... RBC Capital Markets, LLC will act as joint book-running ...
(Date:9/2/2014)... signs monitoring devices market with over 40% market share, ... American and European vital signs monitors markets is expected ... the end of 2013. They have been driving the ... people across these economies. The European market is expected ... rising demand for home health patient monitoring devices due ...
(Date:9/2/2014)... YORK , Sept. 2, 2014 ... is available in its catalogue: Acute ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... 2014 Summary GlobalData,s clinical trial ... H2, 2014" provides data on the Acute Heart ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
... at 59th American Academy of Neurology Annual Meeting, ... /PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a biopharmaceutical company ... targeting,post-transcriptional control processes, today announced positive,interim data from ... patients,with Duchenne muscular dystrophy (DMD) due to a ...
Cached Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5
(Date:9/3/2014)... September 03, 2014 An inspiring story ... be documented in the season finale of “Extreme Weight ... and his teenage daughter from Highlands Ranch, Colo. who ... she weighs 265 pounds. Their challenge is to team ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:9/3/2014)... Gorda, FL (PRWEB) September 03, 2014 ... healthcare delivery, increases patient safety, decreases medical errors, ... providers. , To mark the important role ... in America, IHS and others across the U.S. ... Technology (NHIT) Week , September 16-20, 2014. With ...
(Date:9/3/2014)... 2014 Independent review is a ... evidence-based health care along the continuum. Health plans, ... expertise of accredited independent review organizations (IROs) at ... , As a core function, IROs provide objective, ... of medical necessity. Yet backed by expertise, they ...
(Date:9/2/2014)... IA (PRWEB) September 03, 2014 IMCA ... will kick off on September 1, 2014 at the ... 6, the pre-race ceremony will include a check presentation ... For The Warriors® is a national nonprofit organization that ... the fallen who have sustained physical and psychological wounds ...
(Date:9/2/2014)... concentrated pot might be risky business for women, ... The study is the first to demonstrate sex ... , Psychology professor Rebecca Craft showed that, ... at least 30 percent more sensitive than males ... ingredient in cannabis. Females also develop tolerance to ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... is a statement by ADA President John S. ... (D-Mich.) and Candice Miller (R-Mich.) for introducing the ... that would bolster America,s capacity to respond to ... of the extensive education, training and professionalism of ...
... can divide into two, first it must duplicate its genetic ... of chromosomes then have to be separated from one another ... both daughter cells are genetically identical to the original, or ... called the centrosome, and a copy of the centrosome, position ...
... ONTARIO, CANADA Canada may not be able to ... brain drain of the mid-90s as a result of ... CMAJ published online today http://www.cmaj.ca/cgi/rapidpdf/cmaj.090209 . Health ... the public and government understand the impact of the ...
... (NYSE: RMD ) today announced record revenue and ... the December 2008 quarter was $223.0 million, a 10% increase ... quarter ended December 31, 2007. For the quarter ended ... net income was $33.9 million, an increase of 18% and ...
... study says , , THURSDAY, Feb. 5 (HealthDay News) -- Nearly ... that could lead to paralysis or death, but greater use ... a new study finds. , "Wearing a seat belt is ... against potentially devastating injury," said lead researcher Dr. Marjorie C. ...
... Feb. 5 A coalition of concerned consumer advocate ... Medical Consumers, called on the New York State Legislature ... pharmaceutical company gifts to doctors. This ban would exclude ... focus on gifts valued at over fifty dollars. Pharmaceutical ...
Cached Medicine News:Health News:Statement by ADA President John S. Findley on the Dental Emergency Responder Act Introduced Today by Reps. Stupak and Miller 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 7Health News:Spine Injuries a Common Result of Car Crashes 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 3
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: